摘要
目的研究羟苯磺酸钙治疗糖尿病肾病的近远期疗效及对炎症反应、氧化应激反应的影响。方法选择2017年6月~2019年10月期间收治的Ⅲ期糖尿病肾病患者作为研究对象,随机分为接受常规治疗的对照组、常规治疗联合羟苯磺酸钙治疗的观察组。治疗后3个月时评价疗效;治疗前及治疗后3个月,检测血肌酐(Scr)、血尿素氮(BUN)水平及血清肿瘤坏死因子-α(TNF-α)、白介素-1β(IL-1β)、高迁移率族蛋白B1(HMGB1)、总抗氧化力(T-AOC)、超氧化物歧化酶(SOD)、丙二醛(MDA)的含量;随访治疗后终末期肾脏病的发病情况。结果观察组的总有效率高于对照组(P<0.05);治疗后3个月时,两组的Scr、BUN、TNF-α、IL-1β、HMGB1、MDA水平均低于治疗前,T-AOC、SOD水平均高于治疗前(P<0.05);观察组的Scr、BUN、TNF-α、IL-1β、HMGB1、MDA水平均低于对照组,T-AOC、SOD水平均高于对照组(P<0.05);随访过程中,观察组的终末期肾脏病累积发病率低于对照组(P<0.05)。结论羟苯磺酸钙治疗糖尿病肾病显著改善近远期疗效并抑制炎症反应、氧化应激反应。
Objective To study the short-term and long-term efficacy of calcium dobesilate on diabetic nephropathy and its effects on inflammatory response and oxidative stress response.Methods Patients with stage III diabetic nephropathy in our hospital from June 2017 to October 2019 were selected as the subjects.They were randomly divided into the control group received conventional treatment and the observation group received conventional treatment combined with calcium dobesilate.The curative efficacy was evaluated 3 months after treatment.The levels of serum creatinine(Scr),blood urea nitrogen(BUN)and serum tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1β),high mobility group protein B1(HMGB1),total antioxidant capacity(T-AOC),superoxide dismutase(SOD)and malondialdehyde(MDA)were measured.The incidence of end-stage renal disease after treatment was followed up.Results The total effective rate of the observation group was higher than that of the control group(P<0.05).3 months after treatment,the levels of Scr,BUN and TNF-α,IL-1β,HMGB1 and MDA were lower than those before treatment,and the levels of T-AOC and SOD were higher than those before treatment in the two groups(P<0.05).the levels of Scr,BUN and TNF-α,IL-1β,HMGB1 and MDA in the observation group were lower than those in the control group,and the levels of T-AOC and SOD were higher than those in the control group(P<0.05).During the follow-up,the incidence rate of endstage renal disease in the observation group was lower than that in the control group(P<0.05).Conclusion Calcium dobesilate improves short-term and long-term efficacy and inhibits inflammation and oxidative stress in diabetic nephropathy.
作者
邢媛媛
苏海华
王永红
张婷
滕佳琪
郭超花
XING Yuan-yuan;SU Hai-hua;WANG Yong-hong(Department of Endocrinology and Nephrology,PKUCare CNOOC Hospital,Tianjin 300452,China)
出处
《中国处方药》
2022年第5期68-70,共3页
Journal of China Prescription Drug
关键词
糖尿病肾病
羟苯磺酸钙
终末期肾病
炎症反应
氧化应激反应
Diabetic nephropathy
Calcium hydroxybenzene sulfonate
End stage renal disease
Inflammatory response
Oxidative stress
